17 Lymphoma Clinical Trials in San Francisco, CA (2026)

Q: How do I join a clinical trial in San Francisco?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you.

Recruiting Lymphoma Studies in San Francisco

NCT06717347Recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment ...

San Francisco, CAPHASE31,046 participantsMerck Sharp & Dohme LLC

View Study Details

NCT05978141Recruiting

A Registry for People With T-cell Lymphoma

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more a...

San Francisco, CA1,000 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05006482Recruiting

Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial

This phase III trial compares the effect of geriatric evaluation and management with survivorship health education (GEM-S) to usual care on patient-reported physical function in older survivors of can...

San Francisco, CAPHASE3668 participantsUniversity of Rochester

View Study Details

NCT07226843Recruiting

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously t...

San Francisco, CAPHASE1460 participantsEli Lilly and Company

View Study Details

NCT06911502Recruiting

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma (GOLSEEK-4)

The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants wi...

San Francisco, CAPHASE3400 participantsCelgene

View Study Details

NCT05633615Recruiting

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen recepto...

San Francisco, CAPHASE2396 participantsSWOG Cancer Research Network

View Study Details

NCT06500273Recruiting

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable f...

San Francisco, CAPHASE2250 participantsAllogene Therapeutics

View Study Details

NCT06561048Recruiting

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapse...

San Francisco, CAPHASE3150 participantsCorvus Pharmaceuticals, Inc.

View Study Details

NCT05169515Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and/or CC-99282) in participants with B-cell NHL....

San Francisco, CAPHASE1121 participantsHoffmann-La Roche

View Study Details

NCT06806033Recruiting

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

The main goal of this trial is to study the frequency and severity of cytokine release syndrome (CRS) in participants with diffuse large B-cell lymphoma (DLBCL) who are using a combination of glofitam...

San Francisco, CAPHASE2100 participantsHoffmann-La Roche

View Study Details

NCT04609046Recruiting

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

This phase I trial tests the safety, side effects, best dose and effectiveness of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central...

San Francisco, CAPHASE147 participantsNational Cancer Institute (NCI)

View Study Details

NCT03719105Recruiting

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

Patients are in 2 cohorts: Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in children, adolescents, and y...

San Francisco, CAEARLY_PHASE140 participantsNew York Medical College

View Study Details

NCT04545762Recruiting

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Diff...

San Francisco, CAPHASE136 participantsC. Babis Andreadis

View Study Details

NCT05351593Recruiting

Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma

This is a single arm open-label multicenter phase I/II investigation of combination lenalidomide/Tafasitamab in patients with relapsed central nervous system (CNS) lymphoma. This is the first study to...

San Francisco, CAPHASE135 participantsJames Rubenstein

View Study Details

NCT06522932Recruiting

PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy

This is a phase I/Ib imaging study of granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to family member B (64Cu-GRIP B) Positron Emission Tomography (PET) in patients w...

San Francisco, CAPHASE132 participantsMichael Randall

View Study Details

NCT06252675Recruiting

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

This phase II trial tests the safety and effectiveness of glofitamab given in combination with pirtobrutinib in treating patients with mantle cell lymphoma that has come back after a period of improve...

San Francisco, CAPHASE230 participantsUniversity of California, San Francisco

View Study Details

NCT04656431Recruiting

Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma

This phase I trial evaluates the feasibility of using hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing patients with primary central nervous system lymphoma. This tri...

San Francisco, CAPHASE126 participantsJames Rubenstein

View Study Details

About Lymphoma Clinical Trials in San Francisco

Lymphoma is a cancer of the lymphatic system that affects infection-fighting cells called lymphocytes. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma. Treatment often includes chemotherapy, radiation, immunotherapy, and in some cases stem cell transplant.

There are currently 17 lymphoma clinical trials recruiting participants in San Francisco, CA. These studies are seeking a combined 4,837 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Memorial Sloan Kettering Cancer Center, University of Rochester and 12 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lymphoma Clinical Trials in San Francisco — FAQ

Are there lymphoma clinical trials in San Francisco?

Yes, there are 17 lymphoma clinical trials currently recruiting in San Francisco, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in San Francisco?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you about next steps.

Are clinical trials in San Francisco free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Francisco studies also compensate for your time and travel.

What lymphoma treatments are being tested?

The 17 active trials in San Francisco are testing new therapies including novel drugs, biologics, and treatment approaches for lymphoma.

Data updated July 17, 2026 from ClinicalTrials.gov